T1	Premise 1080 1168	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
T2	Premise 1169 1267	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
T3	Premise 1268 1378	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
T4	Premise 1379 1525	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
T5	Premise 1526 1573	Treatments were well tolerated in the 3 groups.
T6	Premise 1574 1630	No differences in QOL between groups 2 and 3 were found.
T7	Premise 1631 1701	At a median followup of 26 months we observed 12 biochemical relapses.
T8	Claim 1702 1805	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
T9	Claim 1806 1885	Tamoxifen has been shown to be more effective and safe than RT in this setting.
T10	Claim 1886 1968	QOL and sexual function are not negatively influenced by these 2 treatment options
R1	Support Arg1:T10 Arg2:T9	
R2	Support Arg1:T1 Arg2:T8	
R3	Support Arg1:T2 Arg2:T8	
R4	Support Arg1:T3 Arg2:T2	
R5	Support Arg1:T4 Arg2:T8	
R6	Support Arg1:T5 Arg2:T9	
R7	Support Arg1:T6 Arg2:T10	
